Thyroid disease mediated by molecular defects in cell surface and nuclear receptors

American Journal of Medicine

Volumn 105, Issue 6, 1998, Pages 524-538

  Bodenner, Donald L ^a   Lash, Robert W ^b  

^a Div of Endocrinol and Metabolism   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; CELL SURFACE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; THYROID HORMONE; THYROTROPIN RECEPTOR;

GENE MUTATION; GRAVES DISEASE; HORMONE RESISTANCE; HUMAN; HYPERTHYROIDISM; PRIORITY JOURNAL; REVIEW; THYROID DISEASE;

EID: 0032410623     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00319-2     Document Type: Article

References (80)

1. 1. Russo D, Arturi F, Chiefari E, Filetti S. Molecular insights into TSH receptor abnormality and thyroid disease. J Endocrinol Invest. 1997; 20:36-47.
2. 2. Tonacchera M, Van Sande J, Parma J, et al. TSH receptor and disease. Clin Endocrinol. 1996;44:621-633.
3. 3. Paschke R, Ludgate M. The thyrotropin receptor in thyroid diseases. NEJM. 1997;337:1675-1681.
4. 4. Nagayama Y, Kaufman KD, Seto P, Rapoport B. Molecular cloning, sequence and functional expression of the cDNA for the human thyrotropin receptor. Biochem Biophys Res Comm. 1989;165:1184-1190.
5. 5. Libert F, Lefort A, Gerard C, et al. Cloning, sequencing and expression of the human thyrotropin (TSH) receptor: evidence for binding of autoantibodies. Biochem Biophys Res Comm. 1989;165:1250-1255.
6. 6. Spiegel AM, Weinstein LS, Shenker A. Abnormalities in G protein-coupled signal transduction pathways in human disease. J Clin Invest. 1993;92:1119-1125.
7. 7. Pearce S, Trump D. G-Protein-coupled receptors in endocrine disease. QJM. 1995;88:3-8.
8. 8. Laugwitz KL, Allgeier A, Offermanns S, et al. The human thyrotropin receptor: a heptahelical receptor capable of stimulating members of all four G protein families. Proc Natl Acad Sci USA. 1996;93:116-120.
9. 9. Bygrave FL, Roberts HR. Regulation of cellular calcium through signaling cross-talk involves an intricate interplay between the actions of receptors, G-proteins, and second messengers. FASEB J. 1995;9:1297-1303.
10. 10. Van Sande J, Swillens S, Gerard C, et al. In Chinese hamster ovary K1 cells dog and human thyrotropin receptors activate both the cyclic AMP and the phosphatidylinositol 4,5-bisphosphate cascades in the presence of thyrotropin and the cyclic AMP cascade in its absence. Eur J Biochem. 1995;229:338-343.
11. 11. Landis CA, Masters SB, Spada A, et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature. 1989;340:692-696.
12. 12. Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. NEJM. 1991;325:1688-1695.
13. 13. Russo D, Arturi F, Wicker R, et al. Genetic alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab. 1995;80: 1347-1351.
14. 14. O'Sullivan C, Barton CM, Staddon SL, et al. Activating point mutations of the gsp oncogene in human thyroid adenomas. Molec Carcinogen. 1991;4:345-349.
15. 15. Derwahl M. TSH receptor and Gs-alpha gene mutations in the pathogenesis of toxic thyroid adenomas - a note of caution. J Clin Endocrinol Metab. 1996;81:2783-2785.
16. 16. Schwindinger WF, Francomano CA, Levine MA. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA. 1992;89:5152-5156.
17. 17. Van Sande J, Parma J, Tonacchera M, et al. Genetic basis of endocrine disease, somatic and germline mutations of the TSH receptor gene in thyroid diseases. J Clin Endocrinol Metab. 1995;80:2577-2585.
18. 18. Parma J, Van Sande J, Swillens S, et al. Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3′,5′-monophosphate and inositol phosphate-Ca2+ cascades. Molec Endocrinol. 1995;9:725-733.
19. 19. Duprez L, Parma J, Van Sande J, et al. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet. 1994;7:396-401.
20. 20. Kopp P, van Sande J, Parma J, et al. Congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. NEJM. 1995;332:150-154.
21. 21. Russo D, Arturi F, Suarez HG, et al. Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab. 1996;81:1548-1551.
22. 22. Sunthornthepvarakui T, Gottschalk ME, Hayashi Y, Refetoff S. Resistance to thyrotropin caused by mutations in the thyrotropinreceptor gene. NEJM. 1995;332:155-160.
23. 23. Xie J, Pannain S, Pohlenz J, et al. Resistance to thyrotropin (TSH) in three families is not associated with mutations in the TSH receptor or TSH. J Clin Endocrinol Metab. 1997;82:3933-3940.
24. 24. Bahn RS, Dutton CM, Heufelder AE, Sarkar G. A genomic point mutation in the extracellular domain of the thyrotropin receptor in patients with Graves' ophthalmopathy. J Clin Endocrinol Metab. 1994;78:256-260.
25. 25. Bohr UR, Behr M, Loos U. A heritable point mutation in an extracellular domain of the TSH receptor involved in the interaction with Graves' immunoglobulins. Biochimica et Biophysica Acta. 1993;1216:504-508.
26. 26. Prabhakar BS, Fan J-L, Seetharamaiah GS. Thyrotropin-receptormediated diseases: a paradigm for receptor autoimmunity. Immunol Today. 1997;18:437-442.
27. 27. Vitti P, Rotella CM, Valente WA, et al. Characterization of the optimal stimulatory effects of graves' monoclonal and serum immunoglobulin G on adenosine 3′,5′-monophosphate production in fRTL-5 thyroid cells: a potential clinical assay. J Clin Endocrinol Metab. 1983;57:782-791.
28. 28. Zakarija M, McKenzie JM, Munro DS. Immunoglobulin G inhibitor of thyroid-stimulating antibody is a cause of delay in the onset of neonatal Graves' disease. J Clin Invest. 1983;72:1352-1356.
29. 29. Pierce JG, Parsons TF. Glycoprotein hormones: structure and function. Ann Rev Biochem. 1981;50:465-495.
30. 30. Fradkin JE, Eastman RC, Lesniak MA, Roth J. Specificity spillover at the hormone receptor - exploring its role in human disease. NEJM. 1989;320:640-645.
31. 31. Anasti JN, Flack MR, Froehlich J, et al. A potential novel mechanism for precocious puberty in juvenile hypothyroidism. J Clin Endocrinol Metab. 1995;80:276-279.
32. 32. Harada A, Hershman JM, Reed AW, et al. Comparison of thyroid stimulators and thyroid hormone concentrations in the sera of pregnant women. J Clin Endocrinol Metab. 1979;48:793-797.
33. 33. Hershman JM. Trophoblastic tumors. In Bleau RD, ed. Werner and Ingbar's The Thyroid. Philadelphia: Lippincott-Raven; 1996:573-576.
34. 34. Goodwin TM, Hershman JM. Hyperthyroidism due to inappropriate production of human chorionic gonadotropin. Clin Obstet Gynecol. 1997;40:32-44.
35. 35. Ledent C, Dumont JE, Vassart G, Parmentier M. Thyroid expression of an A2 adenosine receptor transgene induces thyroid hyperplasia and hyperthyroidism. EMBO J. 1992;11:537-542.
36. 36. Refetoff S, DeWind LT, DeGroot LJ. Familial syndrome combining deaf-mutism, stuppled epiphyses, goiter and abnormally high PBI: possible target organ refractoriness to thyroid hormone. J Clin Endocrinol Metab. 1967;27:279-294.
37. 37. Refetoff S, Weiss RE, Usala SJ. The syndromes of resistance to thyroid hormone. Endoc Rev. 1993;14:348-399.
38. 38. Refetoff S. Resistance to thyroid hormone and its molecular basis. Acta Paediatrica Japonica. 1994;36:1-15.
39. 39. Refetoff S. Resistance to thyroid hormone: an historical overview. Thyroid. 1994;4:345-349.
40. 40. Beck-Peccoz P, Chatterjee VK. The variable clinical phenotype in thyroid hormone resistance syndrome. Thyroid. 1994;4:225-232.
41. 41. Rivkees SA, Bode HH, Crawford JD. Long-term growth in juvenile acquired hypothyroidism: the failure to achieve normal adult stature. NEJM. 1988;318:599-602.
42. 42. Weiss RE, Refetoff S. Effect of thyroid hormone on growth. Lessons from the syndrome of resistance to thyroid hormone. Endocrinol Metab Clin North Am. 1996;25:719-730.
43. 43. Brucker-Davis F, Skarulis MC, Grace MB, et al. Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of Health Prospective Study. Ann Intern Med. 1995;123:572-583.
44. 44. Leonard CM, Martinez P, Weintraub BD, Hauser P. Magnetic resonance imaging of cerebral anomalies in subjects with resistance to thyroid hormone. Am J Med Genet. 1995;60:238-243.
45. 45. Beck-Peccoz P, Forloni F, Cortelazzi D, et al. Pituitary resistance to thyroid hormones. Horm Res. 1992;38:66-72.
46. 46. Beck-Peccoz P, Brucker-Davis F, Persani L, et al. Thyrotropin-secreting pituitary tumors. Endoc Rev. 1996;17:610-638.
47. 47. Dorey F, Strauch G, Gayno JP. Thyrotoxicosis due to pituitary resistance to thyroid hormones. Successful control with D thyroxine: a study in three patients. Clin Endocrinol. 1990;32:221-228.
48. 48. Beck-Peccoz P, Piscitelli G, Cattaneo MG, Faglia G. Successful treatment of hyperthyroidism due to nonneoplastic pituitary TSH hypersecretion with 3,5,3′-triiodothyroacetic acid (TRIAC). J Endocrinol Invest. 1983;6:217-223.
49. 49. Dulgeroff AJ, Geffner ME, Koyal SN, et al. Bromocriptine and Triac therapy for hyperthyroidism due to pituitary resistance to thyroid hormone. J Clin Endocrinol Metab. 1992;75:1071-1075.
50. 50. Evans RM. The steroid and thyroid hormone receptor superfamily. Science. 1988;240:889-895.
51. 51. Lazar MA, Hodin RA, Darling DS, Chin WW. Identification of a rat c-erbA alpha-related protein which binds deoxyribonucleic acid but does not bind thyroid hormone. Molec Endocrinol. 1988;2:893-901.
52. 52. Lazar MA, Hodin RA, Chin WW. Human carboxyl-terminal variant of alpha-type c-erbA inhibits trans-activation by thyroid hormone receptors without binding thyroid hormone. Proc Natl Acad Sci USA. 1989;86:7771-7774.
53. 53. Hodin RA, Lazar MA, Wintman BI, et al. Identification of a thyroid hormone receptor that is pituitary-specific. Science. 1989;244:76-79.
54. 54. Forrest D, Hanebuth E, Smeyne RJ, et al. Recessive resistance to thyroid hormone in mice lacking thyroid hormone receptor beta: evidence for tissue-specific modulation of receptor function. Embo J. 1996;15:3006-3015.
55. 55. Umesono K, Evans RM. Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell. 1989;57:1139-1146.
56. 56. Brent GA, Harney JW, Chen Y, et al. Mutations of the rat growth hormone promoter which increase and decrease response to thyroid hormone define a consensus thyroid hormone response element. Molec Endocrinol. 1989;3:1996-2004.
57. 57. Umesono K, Murakami KK, Thompson CC, Evans RM. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell. 1991;65:1255-1266.
58. 58. Yang YZ, Burgos-Trinidad M, Wu Y, Koenig RJ. Thyroid hormone receptor variant alpha2. Role of the ninth heptad in DNA binding, heterodimerization with retinoid X receptors, and dominant negative activity. J Biolog Ghem. 1996;271:28235-28242.
59. 59. Au-Fliegner M, Helmer E, Casanova J, et al. The conserved ninth C-terminal heptad in thyroid hormone and retinoic acid receptors mediates diverse responses by affecting heterodimer but not homodimer formation. Molec Cell Biol. 1993;13:5725-5737.
60. 60. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature. 1992;355:446-449.
61. 61. Schrader M, Muller KM, Nayeri S, et al. Vitamin D3-thyroid hormone receptor heterodimer polarity directs ligand sensitivity of transactivation. Nature. 1994;370:382-386.
62. 62. Bogazzi F, Hudson LD, Nikodem VM. A novel heterodimerization partner for thyroid hormone receptor. Peroxisome proliferatoractivated receptor. J Biolog Ghem. 1994;269:11683-11686.
63. 63. Zhang XK, Wills KN, Husmann M, et al. Novel pathway for thyroid hormone receptor action through interaction with jun and fos oncogene activities. Molec Cell Biol. 1991;11:6016-6025.
64. 64. Refetoff S. Resistance to thyroid hormone. Clin Lab Med. 1993;13: 563-581.
65. 65. Yen PM, Brubaker JH, Apriletti JW, et al. Roles of 3,5,3′-triiodothyronine and deoxyribonucleic acid binding on thyroid hormone receptor complex formation. Endocrinology. 1994;134:1075-1081.
66. 66. O'Donnell AL, Rosen ED, Darling DS, Koenig RJ. Thyroid hormone receptor mutations that interfere with transcriptional activation also interfere with receptor interaction with a nuclear protein. Molec Endocrinol 1991;5:94-99.
67. 67. Saatcioglu F, Bartunek P, Deng T, et al. A conserved C-terminal sequence that is deleted in v-ErbA is essential for the biological activities of c-ErbA (the thyroid hormone receptor). Molec Cell Biol. 1993;13:3675-3685.
68. 68. Fondell JD, Roy AL, Roeder RG. Unliganded thyroid hormone receptor inhibits formation of a functional preinitiation complex: implications for active repression. Genes Develop. 1993;7(7B): 1400-1410.
69. 69. Baniahmad A, Ha I, Reinberg D, et al. Interaction of human thyroid hormone receptor beta with transcription factor TFIIB may mediate target gene derepression and activation by thyroid hormone. Proc Natl Acad Sci USA. 1993;90:8832-8836.
70. 70. Shibata H, Spencer TE, Onate SA, et al. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res. 1997;52:141-165.
71. 71. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 1995;377:454-457.
72. 72. Usala SJ, Bale AE, Gesundheit N, et al. Tight linkage between the syndrome of generalized thyroid hormone resistance and the human c-erbA beta gene. Molec Endocrinol. 1988;2:1217-1220.
73. 73. Usala SJ. Thyroid hormone resistance. In Weintraub BD, ed. Molecular Endocrinology. New York: Raven Press; 1995:393-409.
74. 74. Sone T, Scott RA, Hughes MR, et al. Mutant vitamin D receptors which confer hereditary resistance to 1,25-dihydroxyvitamin D3 in humans are transcriptionally inactive in vitro. J Biolog Chem. 1989; 264:20230-20234.
75. 75. Usala SJ, Menke JB, Watson TL, et al. A homozygous deletion in the c-erbA beta thyroid hormone receptor gene in a patient with generalized thyroid hormone resistance: isolation and characterization of the mutant receptor. Molec Endocrinol. 1991;5:327-335.
76. 76. Nagaya T, Madison LD, Jameson JL. Thyroid hormone receptor mutants that cause resistance to thyroid hormone. Evidence for receptor competition for DNA sequences in target genes. J Biolog Chem. 1992;267:13014-13019.
77. 77. Hayashi Y, Janssen OE, Weiss RE, et al. The relative expression of mutant and normal thyroid hormone receptor genes in patients with generalized resistance to thyroid hormone determined by estimation of their specific messenger ribonucleic acid products. J Clin Endocrinol Metab. 1993;76:64-69.
78. 78. Mixson AJ, Hauser P, Tennyson G, et al. Differential expression of mutant and normal beta T3 receptor alleles in kindreds with generalized resistance to thyroid hormone. J Clin Invest. 1993;91:2296-2300.
79. 79. Yoh SM, Chatterjee VK, Privalsky ML. Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors. Mol Endocrinol. 1997; 11:470-480.
80. 80. Collingwood TN, Rajanayagam O, Adams M, et al. A natural transactivation mutation in the thyroid hormone beta receptor: impaired interaction with putative transcriptional mediators. Proc Natl Acad Sci USA. 1997;94:248-253.